A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
Latest Information Update: 31 Jan 2020
At a glance
- Drugs Pixantrone (Primary)
- Indications Cancer; Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors CTI BioPharma
- 18 Oct 2018 Planned End Date changed from 1 Jun 2021 to 10 Jul 2018.
- 18 Oct 2018 Planned primary completion date changed from 1 Jun 2019 to 10 Jul 2018.
- 18 Oct 2018 Planned initiation date changed from 1 Oct 2016 to 24 Oct 2016.